Evidence map›Paper›PMID 25446809›Full record

ArticleTransplant immunology2015

Impaired CD8(+) T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection.

Kymberly M Gowdy, Tereza Martinu, Julia L Nugent, Nicholas D Manzo, Helen L Zhang, Francine L Kelly, Michael J Holtzman, Scott M Palmer

Open access · greenAbstract read
In one paragraph

Article in Transplant immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Modifiable contributing factors to COVID-19: A comprehensive review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2023
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kymberly M GowdyDuke University Medical Center, Durham, NC, 27710, United States. Electronic address: kymberly.gowdy@nih.gov.
Tereza MartinuDuke University Medical Center, Durham, NC, 27710, United States.
Julia L NugentDuke University Medical Center, Durham, NC, 27710, United States.
Nicholas D ManzoDuke University Medical Center, Durham, NC, 27710, United States.
Helen L ZhangDuke University Medical Center, Durham, NC, 27710, United States.
Francine L KellyDuke University Medical Center, Durham, NC, 27710, United States.
Michael J HoltzmanWashington University School of Medicine, St. Louis, MO, 63110, United States.
Scott M PalmerDuke University Medical Center, Durham, NC, 27710, United States; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, United States.
Duke University Hospital · USDuke Medical Center · USWashington University in St. Louis · US

Funding

MATRIX REGULATION OF FIBROPROLIFERATIVE LUNG DISEASEP50HL084917 · NHLBI · DUKE UNIVERSITY · PI WRIGHT, JO RAE · 2006 to 2010
$13.2M
IL-33 AND EXCESS MUCUS PRODUCTIONR01HL121791 · NHLBI · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2014 to 2017
$1.9M
INTERFERON SIGNAL ENHANCERS AS ANTIVIRAL THERAPEUTICSR01AI111605 · NIAID · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2014 to 2017
$1.8M
Genetic Regulation of Lung Transplant OutcomesK24HL091140 · NHLBI · DUKE UNIVERSITY · PI PALMER, SCOTT M · 2008 to 2012
$712k
NHLBI NIH HHS 1 K24 HL91140-01NHLBI NIH HHS 1P50-HL084917-01NHLBI NIH HHS K24 HL091140NHLBI NIH HHS P50 HL084917NHLBI NIH HHS R01 HL121791NIAID NIH HHS R01 AI111605
6 · The paper itself

Abstract

rationaleBone marrow transplant (BMT) recipients experience frequent and severe respiratory viral infections (RVIs). However, the immunological mechanisms predisposing to RVIs are uncertain. Therefore, we hypothesized that antiviral T cell immunity is impaired as a consequence of allogeneic BMT, independent of pharmacologic immunosuppression, and is responsible for increased susceptibility to RVI.

methodsBone marrow and splenocytes from C57BL/6(H2(b)) mice were transplanted into B10.BR(H2(k)) (Allo) or C57BL/6(H2(b)) (Syn) recipients. Five weeks after transplantation, recipient mice were inoculated intranasally with mouse parainfluenza virus type 1 (mPIV-1), commonly known as Sendai virus (SeV), and monitored for relevant immunological and disease endpoints. MAIN

resultsSevere and persistent airway inflammation, epithelial injury, and enhanced mortality are found after viral infection in Allo mice but not in control Syn and non-transplanted mice. In addition, viral clearance is delayed in Allo mice as evidenced by prolonged detection of viral transcripts at Day 15 post-inoculation (p.i.) but not in control mice. In concert with these events, we also detected decreased levels of total and virus-specific CD8(+) T cells, as well as increased T cellexpression of inhibitory receptor programmed death-1 (PD-1), in the lungs of Allo mice at Day 8 p.i. Adoptive transfer of CD8(+) T cells from non-transplanted mice recovered from SeV infection into Allo mice at Day 8 p.i. restored normal levels of viral clearance, epithelial repair, and lung inflammation.

conclusionsTaken together these results indicate that allogeneic BMT results in more severe RVI based on the failure to develop an appropriate pulmonary CD8(+) T cell response, providing an important potential mechanism to target in improving outcomes of RVI after BMT.

Indexed as

Bone Marrow TransplantationImmunity, CellularAdoptive TransferAllograftsAnimalsCD8-Positive T-LymphocytesMaleMiceRespiratory Tract InfectionsRespirovirus InfectionsSendai virusBone marrow transplantCD8(+) T cellsLungRespiratory virus

Identifiers

PMID25446809
PMCPMC4277946
OpenAlexW2004560586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.